Skye Pharma says that it understands why Abbot has decided to return US marketing rights for the Flutiform formoterol fluticasate MDI given the issues raised by the US FDA concerning approval of the drug. According to Skye, it will look for a new licensee if the company can find a way to move forward with the NDA. Read the company’s press release.
